| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00431-005-0070-3 |
| P698 | PubMed publication ID | 16525829 |
| P2093 | author name string | Michael J Dillon | |
| P2860 | cites work | Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research | Q28192643 |
| Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies | Q28298876 | ||
| Immunoablation followed by autologous hematopoietic stem cell infusion for the treatment of severe autoimmune disease. | Q33336533 | ||
| Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). | Q33344252 | ||
| Effective B cell depletion with rituximab in the treatment of autoimmune diseases | Q33346694 | ||
| Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial | Q33976382 | ||
| Etanercept plus standard therapy for Wegener's granulomatosis | Q33984596 | ||
| The use of immunosuppressive and cytotoxic drugs in non-malignant disease | Q34010757 | ||
| Vasculitis from the pediatric perspective | Q34109091 | ||
| Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
| Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases | Q34369159 | ||
| A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome | Q34580488 | ||
| Henoch-Schönlein purpura (treatment and outcome). | Q34709024 | ||
| Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis | Q34799715 | ||
| Current Attitudes to the Therapy of Vasculitis | Q35540941 | ||
| Intravenous immunoglobulin as sole therapy for systemic vasculitis | Q71843650 | ||
| Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin | Q71917500 | ||
| Suppression of human B lymphocyte function by cyclophosphamide | Q72107647 | ||
| Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies | Q73029044 | ||
| Clinical outcome of Schönlein-Henoch purpura nephritis in children | Q73285340 | ||
| Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients | Q73661498 | ||
| Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity | Q73939175 | ||
| [Immunomodulatory effects of intravenous immunoglobulins] | Q74008782 | ||
| Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children | Q74592635 | ||
| T cell activation in rheumatoid synovium is B cell dependent | Q74601890 | ||
| Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis | Q74660140 | ||
| Childhood vasculitis | Q74714038 | ||
| Autologous stem cell transplantation for paediatric-onset polyarteritis nodosa: changes in autoimmune phenotype in the context of reduced diversity of the T- and B-cell repertoires, and evidence for reversion from the CD45RO(+) to RA(+) phenotype | Q77174794 | ||
| Treatment of longstanding active giant cell arteritis with infliximab: report of four cases | Q77406869 | ||
| Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases | Q77571228 | ||
| Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin | Q78095704 | ||
| Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement | Q78223205 | ||
| Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients | Q78328605 | ||
| High-dose intravenous azathioprine pulse treatment in refractory Wegener's granulomatosis | Q80788070 | ||
| Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis | Q81241721 | ||
| B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus | Q81300634 | ||
| Current Status of Tumor Necrosis Factor Inhibition Strategies in the Treatment of Vasculitis | Q35540944 | ||
| Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis | Q35552273 | ||
| The German etanercept registry for treatment of juvenile idiopathic arthritis | Q35553680 | ||
| Infliximab in active early rheumatoid arthritis | Q35553834 | ||
| Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? | Q35838299 | ||
| Retrospective study of plasma exchange in children with systemic lupus erythematosus | Q35858533 | ||
| Risk factors for relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: tools for treatment decisions? | Q36021768 | ||
| What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. | Q36349075 | ||
| Cyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis | Q39253737 | ||
| High dosage intravenous immunoglobulin (IVIG) therapy in therapy-refractory ANCA-negative, necrotizing vasculitis | Q39432951 | ||
| Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis | Q40523209 | ||
| Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients | Q40535853 | ||
| A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies | Q42163521 | ||
| Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. | Q42284427 | ||
| Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids | Q42557663 | ||
| Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study. | Q43419315 | ||
| Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety | Q43607191 | ||
| Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy | Q43837378 | ||
| Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. | Q44037946 | ||
| Induction of remission with infliximab in therapy-refractory Wegener's granulomatosis - Follow-up of six patients | Q44139156 | ||
| An open study of B lymphocyte depletion in systemic lupus erythematosus | Q44183280 | ||
| High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus | Q44278522 | ||
| 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy | Q44285455 | ||
| Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients | Q44402296 | ||
| Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis | Q44419035 | ||
| High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. | Q44470266 | ||
| Maintenance of remission with leflunomide in Wegener's granulomatosis | Q44507162 | ||
| Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. | Q44569286 | ||
| Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab | Q44630712 | ||
| Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis | Q44772811 | ||
| Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation | Q44810026 | ||
| Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis | Q44839339 | ||
| Plasmapheresis therapy for rapidly progressive Henoch-Schönlein nephritis | Q44936916 | ||
| Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis | Q44947447 | ||
| Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis | Q44973880 | ||
| Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis | Q45217518 | ||
| Wegener Granulomatosis: An Analysis of 158 Patients | Q45267316 | ||
| Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients | Q46435124 | ||
| Leflunomide or methotrexate for juvenile rheumatoid arthritis | Q46448238 | ||
| High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide | Q46531955 | ||
| Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative St | Q46970196 | ||
| Renal vasculitis--an update in 2004. | Q47301842 | ||
| Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. | Q54031474 | ||
| Crescentic glomerulonephritis in children | Q67518159 | ||
| A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group | Q68037761 | ||
| Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospect | Q71561244 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 351-357 | |
| P577 | publication date | 2006-03-09 | |
| P1433 | published in | European Journal of Pediatrics | Q15755736 |
| P1476 | title | Vasculitis treatment - new therapeutic approaches | |
| P478 | volume | 165 |
| Q45964920 | Biologic therapy in primary systemic vasculitis of the young. |
| Q40169677 | Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study |
| Q24604335 | Medium-size-vessel vasculitis |
| Q84590347 | Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs |
| Q34245925 | Pediatric vasculitis. |
| Q35011056 | Small vessel vasculitis |
| Q64043724 | Vasculitis in children |
Search more.